Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Tissue Product Sales Stall; Rituxan Driving Immunology

Executive Summary

Sales growth has stalled for Genentech's tissue growth and repair products, with U.S. sales in the fourth quarter of 2007 nearly identical to third quarter totals. Compared to the fourth quarter of 2006, U.S. sales were down 5 percent
Advertisement

Related Content

Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says
Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says
Genentech Meets With Eye Groups Protesting Avastin Sales Restrictions
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
Advertisement
UsernamePublicRestriction

Register

PS049232

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel